MA39847A - Protéines de liaison à l'antigène se liant à wisp1 - Google Patents

Protéines de liaison à l'antigène se liant à wisp1

Info

Publication number
MA39847A
MA39847A MA039847A MA39847A MA39847A MA 39847 A MA39847 A MA 39847A MA 039847 A MA039847 A MA 039847A MA 39847 A MA39847 A MA 39847A MA 39847 A MA39847 A MA 39847A
Authority
MA
Morocco
Prior art keywords
antibodies
wisp1
derivatives
polypeptides
methods
Prior art date
Application number
MA039847A
Other languages
English (en)
Inventor
Gunnar F Kaufmann
Heyue Zhou
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of MA39847A publication Critical patent/MA39847A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention concerne des compositions et des méthodes se rapportant ou dérivées d'anticorps anti-wisp1. Plus spécifiquement, cette invention concerne des anticorps entièrement humains qui se lient à wisp1, des fragments d'anticorps qui se lient à wisp1, des dérivés desdits anticorps, et des polypeptides contenant lesdits fragments qui se lient à wisp1. D'autres modes de réalisation encore concernent des acides nucléiques codant pour ces anticorps, fragments d'anticorps, dérivés et polypeptides, des cellules contenant lesdits polynucléotides, des procédés de préparation des anticorps, fragments d'anticorps, dérivés et polypeptides selon l'invention, et des méthodes pour les utiliser comprenant des méthodes destinées à traiter ou à diagnostiquer les sujets présentant des troubles ou des états pathologiques associés à wisp1. Une méthode destinée à traiter ou à prévenir divers cancers ou maladies inflammatoires et diverses maladies du cœur, des os/articulations ou du poumon est en outre décrite.
MA039847A 2014-04-15 2015-04-14 Protéines de liaison à l'antigène se liant à wisp1 MA39847A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461979704P 2014-04-15 2014-04-15

Publications (1)

Publication Number Publication Date
MA39847A true MA39847A (fr) 2017-02-22

Family

ID=54324703

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039847A MA39847A (fr) 2014-04-15 2015-04-14 Protéines de liaison à l'antigène se liant à wisp1

Country Status (9)

Country Link
US (2) US10272154B2 (fr)
EP (1) EP3131574A4 (fr)
JP (1) JP2017513854A (fr)
KR (1) KR20160138580A (fr)
CN (1) CN106456732A (fr)
AU (1) AU2015247742A1 (fr)
CA (1) CA2945498A1 (fr)
MA (1) MA39847A (fr)
WO (1) WO2015160858A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456732A (zh) 2014-04-15 2017-02-22 索伦托治疗有限公司 结合wisp1的抗体疗法
WO2017083296A1 (fr) * 2015-11-09 2017-05-18 The Children's Hospital Of Philadelphia Glypicane 2 à utiliser en tant que marqueur cancéreux et cible thérapeutique
CN108663524B (zh) * 2018-05-18 2021-06-25 南昌大学第二附属医院 过表达FAT10扰乱WISP1蛋白和mRNA表达促进肝癌的进展
WO2020033398A1 (fr) * 2018-08-06 2020-02-13 The Trustees Of Columbia University In The City Of New York Compositions et procédés pour le traitement de maladies pulmonaires dépendant de cellules atii
CN120305401A (zh) * 2018-10-19 2025-07-15 总医院公司 用于肝病的治疗的组合物和方法
CN109535249B (zh) * 2018-12-12 2021-06-01 广州市第八人民医院 一种单克隆抗体ZKns3G2及其应用
WO2025160400A1 (fr) * 2024-01-26 2025-07-31 Mediar Therapeutics, Inc. Anticorps thérapeutique ciblant la protéine wisp1
WO2025160402A1 (fr) * 2024-01-26 2025-07-31 Mediar Therapeutics, Inc. Anticorps anti-wisp1 et procédés d'utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE406441T1 (de) * 1997-10-29 2008-09-15 Genentech Inc Verwendung des wnt-1 induzierten sekretierten polypeptids wisp-1
US7455834B2 (en) 2002-06-29 2008-11-25 Genentech, Inc. Methods and compositions for modulating and detecting WISP activity
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
ES2886123T3 (es) 2012-01-31 2021-12-16 Regeneron Pharma Anticuerpos anti-asic1 y usos de los mismos
CN106456732A (zh) 2014-04-15 2017-02-22 索伦托治疗有限公司 结合wisp1的抗体疗法

Also Published As

Publication number Publication date
CA2945498A1 (fr) 2015-10-22
JP2017513854A (ja) 2017-06-01
US11318202B2 (en) 2022-05-03
WO2015160858A2 (fr) 2015-10-22
US10272154B2 (en) 2019-04-30
CN106456732A (zh) 2017-02-22
AU2015247742A1 (en) 2016-11-24
EP3131574A2 (fr) 2017-02-22
EP3131574A4 (fr) 2018-01-03
KR20160138580A (ko) 2016-12-05
US20170304442A1 (en) 2017-10-26
WO2015160858A3 (fr) 2015-12-17
US20190224316A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
PH12017500331A1 (en) Antigen binding proteins that bind cxcr5
WO2015160858A3 (fr) Protéines de liaison à l'antigène se liant à wisp1
WO2014194302A3 (fr) Protéines de liaison à l'antigène qui se lient à pd-1
HK1204557A1 (en) Antigen binding proteins that bind pd-l1
WO2017015560A3 (fr) Anticorps thérapeutiques qui se lient à lag3
MX2017011406A (es) Terapeuticos de anticuerpo que se unen a tim3.
WO2013192596A3 (fr) Protéines de liaison à un antigène qui se lient à ccr2
WO2013192594A3 (fr) Protéines de liaison à un antigène qui se lient à c-met
MX2021007947A (es) Terapeuticos de anticuerpo que se unen a ctla4.
MX2017010793A (es) Terapeuticos de anticuerpo que ligan cd137.
WO2016164669A3 (fr) Agents thérapeutiques de type anticorps se liant à cd38
SA523442262B1 (ar) أجسام مضادة للارتباط بـ cd3
PH12019500571A1 (en) Anti-pd-1 antibodies
JO3623B1 (ar) البروتينات المرتبطة بمولد المستضاد st2
HK1214283A1 (zh) 與erbb3結合的抗原結合蛋白
TW201613971A (en) Anti-epidermal growth factor receptor (EGFR) antibodies
MY200162A (en) Anti-gitr antibodies and uses thereof
PH12017500332A1 (en) Antigen binding proteins that bind cxcr3
WO2013191982A3 (fr) Protéines de liaison à un antigène qui se lient à igf1r
WO2016063026A3 (fr) Séquences de liaison sélectives pour la protéine nav
HK1208474A1 (en) Antigen binding proteins that bind egfr
WO2014062245A3 (fr) Protéines liant l'antigène qui lient dll-4
PH12019500434A1 (en) Anti-gm-csf antibodies and uses thereof
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
WO2016040767A3 (fr) Anticorps et épitopes chrdl-1